.jpg?format=webp&width=780)
Radical surgical resection is the standard-of-care treatment for patients with biliary tract cancers. Although disease relapse is common, no clear benefit from adjuvant chemotherapy has been established. Now, results from the ASCOT trial performed in Japan indicate that adjuvant S-1 improves patient outcomes in this setting.
Like
Save
Share